^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rituxan (rituximab)

    i
    Other names: R-105, RG-105, RO-45 2294, IDEC 102, RG105, IDEC-C2B8, RO-452294, R 105, RG 105, IDEC-102, R105, IDEC-C2B8 anti-CD20, RO 45-2294, Ro 45-2294, RO452294, RO 452294, IDEC102, IDEC C2BB
    Company:
    Biogen, Roche, Zenyaku Holdings
    Drug class:
    CD20 inhibitor
    Related drugs:
    22h
    Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)
    P1/2, N=93, Completed, Memorial Sloan Kettering Cancer Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • Matulane (procarbazine hydrochloride)
    1d
    Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. (PubMed, Adv Ther)
    Successful fixed-duration regimens in CLL should achieve deep remission (i.e., undetectable minimal residual disease), sustain long-term progression-free survival, decrease the burden of treatment-related adverse events, and allow for re-treatment with minimal risk of drug resistance. Although fixed-duration treatment represents a positive step forward for most patients with CLL/SLL, the currently approved regimens often fall short in patients at high risk of progression. Continued research and development of next-generation drugs is essential to enhance efficacy and safety, ultimately improving outcomes in all patients with CLL/SLL.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    1d
    An Intestinal Intravascular Large B-Cell Lymphoma Presenting as Small Bowel Ischemia: A Case Report and Literature Review. (PubMed, Cureus)
    The patient was transferred to the hematology department to initiate chemotherapy with the R-CHOP regimen...Intestinal IVLBCL, a rare malignant lymphoma characterized by the selective proliferation of tumor cells within the lumen of small- to medium-sized blood vessels, represents a GI manifestation of IVLBCL. This case report describes a 78-year-old man who presented with vomiting and abdominal pain and was diagnosed with IVLBCL.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    2d
    Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (clinicaltrials.gov)
    P2, N=48, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan
    2d
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=150 --> 90
    Enrollment change
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • TQB2825
    2d
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Enterome | N=60 --> 80 | Trial completion date: May 2032 --> May 2034 | Trial primary completion date: May 2026 --> May 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    2d
    Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) (clinicaltrials.gov)
    P3, N=36, Recruiting, Ottawa Hospital Research Institute | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone
    2d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    3d
    ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)
    The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • ALK fusion • ALK translocation
    |
    Rituxan (rituximab) • carmustine
    3d
    A Single-Center Prospective Randomized Controlled Clinical Study Evaluating the Efficacy of High-Dose Dexamethasone Followed by Sequential Prednisone Maintenance Therapy in Adults with Newly Diagnosed Immune Thrombocytopenia (ChiCTR2600117105)
    P=N/A, N=170, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
    New trial
    |
    Rituxan (rituximab) • prednisone • dexamethasone injection
    3d
    Prospective, single-arm, multicenter clinical study of rituximab combined with cyclophosphamide, mitoxantrone liposomes, vincristine, and prednisone (R-CMOP) regimen in the treatment of previously untreated diffuse large B-cell lymphoma in patients aged 60 years or older or with underlying heart disease (ChiCTR2600117000)
    P=N/A, N=72, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • Marqibo (vincristine liposomal) • Duoenda (mitoxantrone liposomal) • vindesine
    3d
    Use of Telitacicept in Rescue Therapy for Rituximab (RTX)-Refractory/Relapsed Membranous Nephropathy (MN) (ChiCTR2600115890)
    P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New trial
    |
    Rituxan (rituximab)